Skip to content
Company Analysis

Charles River Laboratories Inte CRL

A comprehensive view of key metrics, scores, and financial health for Charles River Laboratories Inte

Overview of Charles River Laboratories International, Inc.

CRL NYQ
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics Mid Cap
Charles River Laboratories International, Inc. (CRL), is a Mid Cap company, in the Diagnostics & Research industry, last closed at $187.51, about 28.1% overvalued vs fair value, +25.5% 1Y return, placing in the top 25% of its sector.
Metrics Rev Growth -0.9% ROE -4.4% Gross Margin 30.5%
USD 187.51
-0.29%
(Delayed)
• Vol 90d: 54.6%
52-Week Range
Market Cap
$8.97B
Enterprise Value
$11.82B
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Fair
Growth
Weak
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Fair
Completeness: 82%
Confidence: 89%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.criver.com
HQ Wilmington, MA
Employees 18,300
Fiscal year Dec 31

Next Events

Earnings Aug 5 Estimated

Fair Value Snapshot

Bear Base Bull
$119
$135
$152
Current: $187.51 -28% vs base

Engine Room Money Flow™

Mid Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$4.0B
-0.9%%
Gross Profit
$1.2B
-8%%
Operating Income (GAAP)
$507.8M
14.8%%
EBITDA
$911.2M
56.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
30.5%
Poor

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
1/2
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Charles River Laboratories Inte's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
56
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
36
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 97% Coverage
Trade-Off Triangle Visualization A ternary plot showing CRL's balance between Growth (13.7%), Profitability (46.5%), and Safety (39.8%). Growth 14% Safety 40% Profitability 47%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

20th percentile vs peers
21
Key Signals
Rev Growth YoY -0.9% 28p Revenue CAGR 3Y 0.3% 30p EPS Growth YoY -97.8% 10p EPS CAGR 3Y -70.3% 1p
Strengths
  • D/E Ratio in top 20% of peers (96.9%, 84th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • FCF Margin in top 20% of peers (12.9%, 81th percentile)
Risks
  • Growth in bottom 20% of peers (percentile: 20)
  • EPS Growth YoY in bottom 20% of peers (-97.8%)

Profitability

70th percentile vs peers
70
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

60th percentile vs peers
60
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Charles River Laboratories Inte.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$134.80
- - -
-28.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000